Vaxcyte, Inc. (PCVX)Healthcare | Biotechnology | San Carlos, United States | NasdaqGS
59.84 USD
-1.32
(-2.158%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 59.50 -0.33 (-0.335%) ⇩ (Aug. 28, 2026, 7:30 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 2:53 a.m. EDT
The investment case for Vaxcyte is currently fractured by a severe disconnect between its lofty analyst targets and its deteriorating operational reality. While the balance sheet remains robust with minimal debt and ample cash reserves, the company is burning through capital rapidly, posting significant losses in both operating and free cash flow. This financial bleed is reflected in the stock's brutal performance over the last five years, which saw a cumulative decline of nearly 37%, capped off by a catastrophic 58% drop in the most recent fiscal year. The market has rightly punished this recent failure, yet the stock trades at a premium to its book value, ignoring the fact that the forward earnings estimates remain deeply negative. On the short end, the options market screams caution; the sheer volume of put buying suggests investors are bracing for further pain rather than betting on a recovery. Until the company can demonstrate a path to profitability or a major catalyst that justifies the current valuation gap, the risk-reward profile remains skewed heavily against the buyer. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.143968 |
| AutoARIMA | 0.143968 |
| MSTL | 0.145540 |
| AutoTheta | 0.163196 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 34% |
| H-stat | 5.55 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.090 |
| Excess Kurtosis | -0.46 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 4.186 |
| Market Cap | 8,903,763,968 |
| Forward P/E | -8.29 |
| Beta | 1.21 |
| Website | https://vaxcyte.com |
As of Aug. 22, 2026, 2:53 a.m. EDT: Speculators are positioning heavily for downside protection, evidenced by massive open interest in out-of-the-money puts expiring in October and December, particularly at strikes significantly below the current price. Conversely, call activity is sparse and concentrated near the money, with very little speculative volume in deep out-of-the-money calls despite the high implied volatility suggesting a fear of a crash rather than a rally.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.9377376 |
| Address1 | 825 Industrial Road |
| Address2 | Suite 300 |
| All Time High | 121.055 |
| All Time Low | 15.51 |
| Ask | 76.51 |
| Ask Size | 2 |
| Audit Risk | 3 |
| Average Analyst Rating | 1.3 - Strong Buy |
| Average Daily Volume10 Day | 877,110 |
| Average Daily Volume3 Month | 1,322,208 |
| Average Volume | 1,322,208 |
| Average Volume10Days | 877,110 |
| Beta | 1.21 |
| Bid | 43.9 |
| Bid Size | 2 |
| Board Risk | 6 |
| Book Value | 19.048 |
| City | San Carlos |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 59.835 |
| Current Ratio | 5.724 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 61.805 |
| Day Low | 59.485 |
| Debt To Equity | 4.186 |
| Display Name | Vaxcyte |
| Earnings Call Timestamp End | 1,771,968,600 |
| Earnings Call Timestamp Start | 1,771,968,600 |
| Earnings Timestamp End | 1,793,736,000 |
| Earnings Timestamp Start | 1,793,736,000 |
| Ebitda | -1,148,780,032 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -6.557 |
| Enterprise Value | 7,532,370,944 |
| Eps Current Year | -8.19714 |
| Eps Forward | -7.21714 |
| Eps Trailing Twelve Months | -7.47 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 57.1559 |
| Fifty Day Average Change | 2.6791 |
| Fifty Day Average Change Percent | 0.04687355 |
| Fifty Two Week Change Percent | 93.77376 |
| Fifty Two Week High | 65.0 |
| Fifty Two Week High Change | -5.165001 |
| Fifty Two Week High Change Percent | -0.07946155 |
| Fifty Two Week Low | 30.81 |
| Fifty Two Week Low Change | 29.025 |
| Fifty Two Week Low Change Percent | 0.9420643 |
| Fifty Two Week Range | 30.81 - 65.0 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,591,968,600,000 |
| Float Shares | 136,484,201 |
| Forward Eps | -7.21714 |
| Forward P E | -8.29068 |
| Free Cashflow | -485,755,264 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 507 |
| Fullday Change | -1.32 |
| Fullday Change Percent | -2.15845 |
| Fullday Price | 59.5 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.00485 |
| Held Percent Institutions | 1.13452 |
| Implied Shares Outstanding | 148,805,278 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; VAX-GI, a novel preclinical vaccine candidate for the treatment of dysentery and shigellosis, which is caused by Shigella bacteria; and VAX-XL, a third-generation pneumococcal conjugate vaccine. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California. |
| Long Name | Vaxcyte, Inc. |
| Market | us_market |
| Market Cap | 8,903,763,968 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_307500026 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -1,064,260,992 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 9,093,490,538 |
| Number Of Analyst Opinions | 9 |
| Open | 61.06 |
| Operating Cashflow | -881,233,024 |
| Operating Margins | 0.0 |
| Overall Risk | 7 |
| Payout Ratio | 0.0 |
| Phone | 650 837 0111 |
| Post Market Change | -0.33499908 |
| Post Market Change Percent | -0.55987144 |
| Post Market Price | 59.5 |
| Post Market Time | 1,787,959,804 |
| Previous Close | 61.155 |
| Price Eps Current Year | -7.299497 |
| Price Hint | 2 |
| Price To Book | 3.1412745 |
| Profit Margins | 0.0 |
| Quick Ratio | 5.481 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.27273 |
| Region | US |
| Regular Market Change | -1.32 |
| Regular Market Change Percent | -2.15845 |
| Regular Market Day High | 61.805 |
| Regular Market Day Low | 59.485 |
| Regular Market Day Range | 59.485 - 61.805 |
| Regular Market Open | 61.06 |
| Regular Market Previous Close | 61.155 |
| Regular Market Price | 59.835 |
| Regular Market Time | 1,787,947,200 |
| Regular Market Volume | 759,733 |
| Return On Assets | -0.22606 |
| Return On Equity | -0.36514 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 148,805,278 |
| Shares Percent Shares Out | 0.0994 |
| Shares Short | 14,796,265 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 14,231,919 |
| Short Name | Vaxcyte, Inc. |
| Short Percent Of Float | 0.1 |
| Short Ratio | 15.42 |
| Source Interval | 15 |
| State | CA |
| Symbol | PCVX |
| Target High Price | 163.0 |
| Target Low Price | 67.0 |
| Target Mean Price | 109.0 |
| Target Median Price | 110.0 |
| Total Cash | 1,486,838,016 |
| Total Cash Per Share | 9.992 |
| Total Debt | 115,445,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -7.47 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 53.620625 |
| Two Hundred Day Average Change | 6.2143745 |
| Two Hundred Day Average Change Percent | 0.11589523 |
| Type Disp | Equity |
| Volume | 759,733 |
| Website | https://vaxcyte.com |
| Zip | 94,070 |